Your download is now in progress and you may close this window

Did you know that with a free Taylor & Francis Online account you can gain access to the following benefits?

Choose new content alerts to be informed about new research of interest to you
Easy remote access to your institution's subscriptions on any device, from any location
Save your searches and schedule alerts to send you new results
Export your search results into a .csv file to support your research

Have an account?
Login now Don't have an account?
Register for free

Login or register to access this feature

Have an account?
Login now Don't have an account?
Register for free

Choose new content alerts to be informed about new research of interest to you
Easy remote access to your institution's subscriptions on any device, from any location
Save your searches and schedule alerts to send you new results
Export your search results into a .csv file to support your research

Search in:

Advanced search

Neuropsychiatric Disease and Treatment Volume 11, 2015 - Issue

Submit an article Journal homepage

Open access

Views

CrossRef citations to date

Altmetric

Original Research

Efficacy comparison of duloxetine and SSRIs at doses approved in Japan

Eiji Harada1 Medical Science, Eli Lilly Japan K.K, Kobe, JapanCorrespondence[email protected]

Alexander Schacht2 Global Statistical Sciences, Eli Lilly and Company, Bad Homburg, Germany

Tsukasa Koyama3 Clinical Research Center, Ohyachi Hospital, Sapporo, Japan

Lauren B Marangell4 Eli Lilly and Company, Indianapolis, IN, USA;5 The University of Texas Health Science Center, Houston, TX, USA

Toshinaga Tsuji6 Medical Affairs, Shionogi & Co Ltd, Osaka, Japan

Rodrigo Escobar4 Eli Lilly and Company, Indianapolis, IN, USA

Pages 115-123 | Published online: 12 Jan 2015

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

Citations (3)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (3)

Martin Plöderl & Michael P. Hengartner. (2019) Guidelines for the pharmacological acute treatment of major depression: conflicts with current evidence as demonstrated with the German S3-guidelines. BMC Psychiatry 19:1.
Crossref

Hirofumi Tokuoka, Hitoshi Takahashi, Akichika Ozeki, Atsushi Kuga, Aki Yoshikawa, Toshinaga Tsuji & Madelaine M. Wohlreich. (2016) Trajectories of depression symptom improvement and associated predictor analysis: An analysis of duloxetine in double-blind placebo-controlled trials. Journal of Affective Disorders 196, pages 171-180.
Crossref

Masoud Behzadifar, Abouzar Keshavarzi, Abed Tofighian, Mohammad Rastian, Mohammad Zobidi & Ali Akbari Sari. (2015) Efficacy and Safety of Vortioxetine and Duloxetine 60 mg Compared Placebo for the Treatment of Major Depressive Disorder: A Systematic Review and Meta-Analysis. Journal of Behavioral and Brain Science 05:10, pages 430-439.
Crossref

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references